PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer Article / By Mike Echalaz PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer Read More »
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer Article / By Mike Echalaz The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer Read More »
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis Article / By Mike Echalaz CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis Read More »
Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy Article / By Mike Echalaz Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy Read More »
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Article / By Mike Echalaz Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Read More »
